Indian Journal of PsychiatryIndian Journal of Psychiatry
Home | About us | Current Issue | Archives | Ahead of Print | Submission | Instructions | Subscribe | Advertise | Contact | Login 
    Users online: 141 Small font sizeDefault font sizeIncrease font size Print this article Email this article Bookmark this page
Search Again
 Back
 Table of Contents
 
 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Article Access Statistics
 Reader Comments
 Email Alert
 Add to My List
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1227    
    Printed72    
    Emailed1    
    PDF Downloaded144    
    Comments [Add]    

Recommend this journal

 
ORIGINAL RESEARCH PAPER
Year : 2005  |  Volume : 47  |  Issue : 1  |  Page : 30-32

A double-blind randomized trial between risperidone and haloperidol in drug-naive patients with paranoid schizophrenia


1 Department of Psychiatry, S.V. Medical College, Tirupati 517507, Tamil Nadu, India
2 NIMHANS, Bangalore, India

Correspondence Address:
K J Vijay Sagar
Department of Psychiatry, S.V. Medical College, Tirupati 517507, Tamil Nadu
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0019-5545.46071

Rights and Permissions

Background: Haloperidol is highly effective against the positive symptoms of schizophrenia, but is less effective against the negative symptoms. It also produces marked extrapyramidal symptoms. The newer atypical antipsychotics are believed to have an equal efficacy with a favourable side-effect profile. Aim: We assessed the effects of risperidone and haloperidol in patients with schizophrenia to compare their clinical efficacy and side-effect profile. Methods: A double-blind, randomized, prospective, comparative trial with a parallel treatment design of 6 weeks' duration was undertaken on 46 drug-naive schizophrenics to compare the efficacy and adverse effects profile of risperidone and haloperidol. Results: The study showed no difference in the positive and negative subscale scales on the Positive and Negative Syndrome Scale (PANSS). However, risperidone was found to have an edge over haloperidol in improving the general psychopathology as well as in bringing about global improvement. Conclusion: Of the two drugs, the adverse effect profile of risperidone is better, with less need for the use of antiparkinsonian medication.



[FULL TEXT] [PDF]*

        

Print this article         Email this article